At the AD/PD 2026, Roche showcased new five-year data from the Phase II PASADENA trial (NCT03100149) involving prasinezumab.
Stocktwits on MSN
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data
The analyst noted that Ocugen has three clinical stage programs in rare and non-rare retinal diseases including OCU400, ...
IQVIA Holdings Inc. (NYSE:IQV) is one of the 11 Best Affordable Growth Stocks to Buy Now. On March 3, analysts at RBC Capital ...
Monte Rosa Therapeutics Inc. reports fourth-quarter and full-year 2025 results Thursday, closing out a year marked by promising clinical data but facing investors’ questions about revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results